Browse the corpus

Emtricitabine is a nucleoside reverse transcriptase inhibitor widely used in combination antiretroviral therapy for the treatment of HIV-1 and HIV-2 infections, management of hepatitis B virus, and as part of pre-exposure prophylaxis to prevent HIV acquisition. This activity introduces clinicians to emtricitabine’s pharmacology, mechanism of action, safety profile, monitoring requirements, and drug interactions, highlighting its FDA-approved uses as well as relevant off-label considerations. Special attention focuses on its role in post-exposure prophylaxis, use during pregnancy, and in patients with coexisting conditions such as hepatitis C, providing a comprehensive foundation for evidence-based patient care. This activity explores the integration of emtricitabine in HIV prevention and treatment, emphasizing the vital role of an interprofessional healthcare team in optimizing outcomes. Through focused discussions on patient risk assessment, dosing strategies, adherence counseling, and laboratory monitoring, the activity enhances clinician competence in individualizing therapy and minimizing adverse effects. By fostering interprofessional collaboration, promoting shared decision-making, and strengthening patient education, healthcare providers improve the effectiveness of emtricitabine-based regimens and advance the quality of care for individuals living with or at risk for HIV infection. Objectives: Identify the mechanism of action and pharmacologic profile of emtricitabine in HIV treatment and prevention. Implement patient education strategies on proper use, adherence, and potential adverse effects. Assess patients for contraindications, comorbidities, and potential drug interactions before initiating emtricitabine therapy. Collaborate with interprofessional healthcare teams to coordinate comprehensive care for individuals receiving emtricitabine therapy while optimizing adherence and minimizing the risk of adverse effects. Access free multiple choice questions on this topic.

Signs and Symptoms of Overdose Emtricitabine, along with the other drugs in the NRTI category, can interact with mitochondrial DNA polymerase, leading to myopathy and neuropathy. This mitochondrial toxicity is also associated with hepatic steatosis and lactic acidosis. Emtricitabine has not been shown to have any adverse effects on the mitochondrial function of developing fetuses and is not known to be teratogenic. There is no evidence that emtricitabine affects the fertility rates of women taking the drug.[3] Acute intentional overdose involving emtricitabine–tenofovir has been reported to cause severe lactic acidosis requiring intubation for airway protection.[26] Management of Overdose If an overdose occurs, the patient should be closely monitored for signs of toxicity, and standard supportive care should be provided as needed. Hemodialysis can remove a portion of the emtricitabine dose during a 3-hour session. The effectiveness of emtricitabine removal by peritoneal dialysis has not been established.

HIV prevention and treatment require an integrated, interprofessional healthcare team consisting of primary care physicians, physician associates, nurse practitioners, specialty physicians, nurses, office staff, pharmacists, and laboratory personnel. Effective HIV prevention begins with health education on safer sex practices provided by the primary care physician. Primary care providers should maintain a nonjudgmental approach and be skilled in obtaining a detailed sexual history using open-ended questions, as well as assessing social history, including alcohol and drug use.[27] At each patient visit to the primary care clinic, a risk assessment for HIV acquisition should be performed.[4] In addition to HIV testing discussions in the primary care setting, emergency departments and obstetrician-gynecologists should also offer routine HIV testing.[4] For individuals at high risk, the benefits of protection from daily PrEP should be discussed with patients. The recommended daily PrEP regimen is a single once-daily tablet containing emtricitabine and tenofovir. Patients should receive comprehensive education from primary care providers, nurses, and pharmacists before initiating and while using PrEP. These guidelines include using PrEP consistently for 1 week before sexual activity to allow for adequate drug levels to build in rectal, penile, and vaginal tissue. Patients should also receive reminders to continue PrEP for 1 week after the last sexual encounter if they want to discontinue this medication.[4] Nurses should review these educational points before discharge to reinforce understanding and ensure that patients are well-informed about proper PrEP use. Before prescribing PrEP, all patients should undergo HIV testing using an antigen-antibody assay to confirm HIV-negative status.[4] Other recommendations before prescribing PrEP include measuring serum creatinine, GFR, and hepatitis B surface antigen. Patients should have a follow-up visit 1 month after starting PrEP to evaluate adherence and adverse effects, and then every 3 months for repeat HIV testing. If a patient acquires HIV while on PrEP, ART should be initiated promptly.[4][28] Annual HCV testing is also recommended for individuals on long-term PrEP therapy.

Before prescribing PrEP, all patients should undergo HIV testing using an antigen-antibody assay to confirm HIV-negative status.[4] Other recommendations before prescribing PrEP include measuring serum creatinine, GFR, and hepatitis B surface antigen. Patients should have a follow-up visit 1 month after starting PrEP to evaluate adherence and adverse effects, and then every 3 months for repeat HIV testing. If a patient acquires HIV while on PrEP, ART should be initiated promptly.[4][28] Annual HCV testing is also recommended for individuals on long-term PrEP therapy. Creatinine measurements should be performed every 6 months or more frequently for patients taking medications for hypertension or diabetes, those aged 50 or older, and those with a GFR of less than 90 mL/min.[4] Each follow-up visit should also include counseling on safe sex practices, such as condom use and adherence to daily medication. Any patient with HBV infection who is on PrEP containing emtricitabine should be closely monitored upon discontinuation of the medication, as HBV reactivation may lead to liver injury.[27] Every patient should receive at least one HIV test in their lifetime, with certain populations requiring more frequent testing. Men who have sex with men, transgender women, and individuals who use IV drugs should undergo HIV testing at least annually and, in some cases, as often as every 3 months. Patients who present with sexually transmitted infections and HCV infection should be screened for HIV more frequently.[4] When performing HIV testing, the healthcare team should explain the testing methodology, the expected time for results, and the requirement to report positive results to the state health department.[29] HIV testing recommendations include a combination antibody-antigen assay or a combination antibody assay with nucleic acid testing. Further testing of the HIV viral load is recommended before prescribing ART.[4]

Every patient should receive at least one HIV test in their lifetime, with certain populations requiring more frequent testing. Men who have sex with men, transgender women, and individuals who use IV drugs should undergo HIV testing at least annually and, in some cases, as often as every 3 months. Patients who present with sexually transmitted infections and HCV infection should be screened for HIV more frequently.[4] When performing HIV testing, the healthcare team should explain the testing methodology, the expected time for results, and the requirement to report positive results to the state health department.[29] HIV testing recommendations include a combination antibody-antigen assay or a combination antibody assay with nucleic acid testing. Further testing of the HIV viral load is recommended before prescribing ART.[4] Patients who test positive for HIV should be referred to an infectious disease specialist or an HIV specialist. Before prescribing ART, additional testing of HIV viral load and genotype should be conducted, as genotype testing identifies potential drug resistance for the patient’s specific HIV strain.[4] Comorbidities of these patients should be carefully documented in the electronic health record, especially if the patient has concurrent HBV. Liver enzymes and HBV DNA viral load may increase if emtricitabine is discontinued abruptly.[3] Therefore, primary care and infectious disease providers should monitor patients for signs of liver damage for several weeks after discontinuing emtricitabine.[3] Mental health should also be addressed for newly diagnosed patients and those living with HIV, with referrals to psychiatry or counseling provided as needed.

Patients who test positive for HIV should be referred to an infectious disease specialist or an HIV specialist. Before prescribing ART, additional testing of HIV viral load and genotype should be conducted, as genotype testing identifies potential drug resistance for the patient’s specific HIV strain.[4] Comorbidities of these patients should be carefully documented in the electronic health record, especially if the patient has concurrent HBV. Liver enzymes and HBV DNA viral load may increase if emtricitabine is discontinued abruptly.[3] Therefore, primary care and infectious disease providers should monitor patients for signs of liver damage for several weeks after discontinuing emtricitabine.[3] Mental health should also be addressed for newly diagnosed patients and those living with HIV, with referrals to psychiatry or counseling provided as needed. The healthcare team should maintain accurate records of patients’ medication refills and appointment attendance.[4] Administrative staff, including front desk personnel, can assist by reminding patients of appointments and follow-ups. Each visit provides an opportunity to discuss adherence to ART, evaluate patient understanding of medications, and reiterate the importance of safe sex practices and disclosing their HIV status. Screening the social factors of this patient population is vital to ensure that these patients can afford their medications, understand how to take them, have support from family and friends, and have access to proper transportation to and from the physician’s office. In some cases, involving a social worker may be necessary to address these social determinants of health and ensure optimal care for patients living with HIV.

The healthcare team should maintain accurate records of patients’ medication refills and appointment attendance.[4] Administrative staff, including front desk personnel, can assist by reminding patients of appointments and follow-ups. Each visit provides an opportunity to discuss adherence to ART, evaluate patient understanding of medications, and reiterate the importance of safe sex practices and disclosing their HIV status. Screening the social factors of this patient population is vital to ensure that these patients can afford their medications, understand how to take them, have support from family and friends, and have access to proper transportation to and from the physician’s office. In some cases, involving a social worker may be necessary to address these social determinants of health and ensure optimal care for patients living with HIV. Finally, healthcare providers are responsible for educating patients about the short-term use of medications such as emtricitabine, in combination with other antiretroviral agents, as PEP.[10] Patients should also be educated about the risks of HIV exposure and informed about when and how to seek prompt medical attention. Standardized protocols should be established in clinics and hospitals to manage potential HIV exposure effectively. These protocols should include determining the HIV status of the individual requesting PEP therapy and, if possible, the HIV status of the subject with whom the patient was in contact.[10] Clinicians should also assess the timing and frequency of HIV exposure, the level of risk, and the possibility of other sexually transmitted infections.[10] Patient education should further emphasize safe sex practices, methods to minimize occupational exposure, and the importance of follow-up to monitor adherence and treatment-related adverse effects.[10]

Finally, healthcare providers are responsible for educating patients about the short-term use of medications such as emtricitabine, in combination with other antiretroviral agents, as PEP.[10] Patients should also be educated about the risks of HIV exposure and informed about when and how to seek prompt medical attention. Standardized protocols should be established in clinics and hospitals to manage potential HIV exposure effectively. These protocols should include determining the HIV status of the individual requesting PEP therapy and, if possible, the HIV status of the subject with whom the patient was in contact.[10] Clinicians should also assess the timing and frequency of HIV exposure, the level of risk, and the possibility of other sexually transmitted infections.[10] Patient education should further emphasize safe sex practices, methods to minimize occupational exposure, and the importance of follow-up to monitor adherence and treatment-related adverse effects.[10] Patients seeking PEP should be evaluated by a healthcare professional who can stratify risk factors and determine the need for ART. PEP therapy should be readily available to all healthcare workers, along with laboratory testing for those experiencing occupational exposure. Testing for occupational exposure should be promoted and simplified, so healthcare professionals can feel comfortable coming forward to protect their health. An interprofessional team approach and effective communication among physicians, advanced practice providers, pharmacists, and nurses are crucial to minimizing potential adverse effects and enhancing patient outcomes related to emtricitabine therapy.